World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
92
Citations
40521
World Ranking
11133
National Ranking
350

Val Gebski publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Val Gebski sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 623 publications — 74th percentile

74% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Val Gebski D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Val Gebski sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 92 D-Index — 45th percentile

45% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Val Gebski is affiliated with the University of Sydney in Australia, focusing their research primarily within the field of Medicine. Their work spans various critical subfields including Oncology, Pulmonary and Respiratory Medicine, Surgery, Obstetrics and Gynecology, and Epidemiology.

Their research topics concentrate on cancer and treatment methodologies, with notable emphasis on:

  • Endometrial and Cervical Cancer Treatments
  • Ovarian Cancer Diagnosis and Treatment
  • Pancreatic and Hepatic Oncology Research
  • Gastric Cancer Management and Outcomes
  • Esophageal Cancer Research and Treatment
  • PARP Inhibition in Cancer Therapy
  • Breast Cancer Treatment Studies

Gebski has contributed to multiple frequent publication venues, highlighting their active engagement in clinical oncology and cancer research. These venues include:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • Gynecologic Oncology
  • International Journal of Gynecological Cancer
  • European Journal of Cancer

A selection of recent papers featuring Gebski's research demonstrates a focus on chemotherapy and cancer treatment trials, including the following:

  • "Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial" (2020), published in The Lancet Diabetes & Endocrinology
  • "Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial" (2023), published in The Lancet Oncology
  • "Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup" (2022), published in The Lancet Oncology
  • "Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma Determine Response to SLC7A11 Inhibition" (2021), published in Cancer Research
  • "Adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: The randomized phase III OUTBACK Trial (ANZGOG 0902, RTOG 1174, NRG 0274)." (2021), published in Journal of Clinical Oncology

Gebski collaborates often with several researchers, indicating a networked approach within their field. Frequent co-authors include:

  • Andreas Obermair
  • Kate Wilson
  • John Zalcberg
  • Timothy Price
  • Matthew Burge

Best Publications

  • Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

    Eric Pujade-Lauraine;Jonathan A Ledermann;Frédéric Selle;Val Gebski

  • Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis

    Katrin M Sjoquist;Bryan H Burmeister;B Mark Smithers;B Mark Smithers;John R Zalcberg

  • Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer

    Pedro Tomas Ramirez;Michael Frumovitz;Rene Pareja;Aldo Lopez

  • Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis

    Val Gebski;Bryan Burmeister;B Mark Smithers;Kerwyn Foo

  • Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial.

    Bryan H Burmeister;B Mark Smithers;Val Gebski;Lara Fitzgerald

  • Effect of Laparoscopic-Assisted Resection vs Open Resection on Pathological Outcomes in Rectal Cancer: The ALaCaRT Randomized Clinical Trial

    Andrew R. L. Stevenson;Andrew R. L. Stevenson;Michael J. Solomon;John W. Lumley;Peter Hewett

  • Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies.

    Alan Coates;Val Gebski;James F. Bishop;Peter N. Jeal

  • Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-Analysis.

    Chee Khoon Lee;Chee Khoon Lee;Johnathan Man;Sally Lord;Matthew Links

  • Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse

    Eric Pujade-Lauraine;Uwe Wagner;Elisabeth Aavall-Lundqvist;Val Gebski

  • Lymphomas in Eμ-Pim1 Transgenic Mice Exposed to Pulsed 900 MHz Electromagnetic Fields

    Michael H. Repacholi;Antony Basten;Val Gebski;Denise Noonan

  • Randomised trial of SIR-Spheres® plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer

    B. Gray;G. Van Hazel;M. Hope;M. Burton

  • Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol Levels in Statin-Intolerant Patients: The GAUSS Randomized Trial

    David Sullivan;Anders G. Olsson;Rob Scott;Jae B. Kim

  • Impact of EGFR Inhibitor in Non–Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis

    Chee Khoon Lee;Chris Brown;Richard J. Gralla;Vera Hirsh

  • SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma

    Pierce K.H. Chow;Mihir Gandhi;Say Beng Tan;Maung Win Khin

  • Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis.

    Chee Khoon Lee;Chee Khoon Lee;Johnathan Man;Sally Lord;Wendy Cooper;Wendy Cooper

  • Capecitabine, Bevacizumab, and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study

    Niall C. Tebbutt;Kate Wilson;Val J. Gebski;Michelle M. Cummins

  • Safety and efficacy of vertebroplasty for acute painful osteoporotic fractures (VAPOUR): a multicentre, randomised, double-blind, placebo-controlled trial

    William Clark;Paul Bird;Peter Gonski;Peter Gonski;Terrence H Diamond;Terrence H Diamond

  • Prognostic value of quality-of-life scores during chemotherapy for advanced breast cancer. Australian New Zealand Breast Cancer Trials Group.

    A Coates;V Gebski;D Signorini;P Murray

  • SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer

    Guy A. van Hazel;Volker Heinemann;Navesh K. Sharma;Michael P.N. Findlay

  • CONSORT 2010 Statement: Updated guidelines for reporting parallel group randomized trials

    K F Schulz;D G Altman;D Moher;D Moher;V Barbour

Frequent Co-Authors

Anthony C. Keech
Anthony C. Keech University of Sydney
John Simes
John Simes University of Sydney
Michael Friedlander
Michael Friedlander University of New South Wales
David Goldstein
David Goldstein University of New South Wales
John R. Zalcberg
John R. Zalcberg Monash University
Alicia J. Jenkins
Alicia J. Jenkins University of Sydney
John F. Forbes
John F. Forbes University of Limerick
Volker Heinemann
Volker Heinemann Ludwig-Maximilians-Universität München
Richard F. Kefford
Richard F. Kefford Macquarie University
Alan S. Coates
Alan S. Coates University of Sydney

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you're considering a career in medicine but want to explore flexible educational routes, a range of online degree options may align with your ambitions. For registered nurses aiming to advance quickly, there are dnp programs without dissertation that allow you to earn the highest clinical degree with fewer research requirements.

Those interested in entering the workforce sooner can look into fast track lpn programs. These allow students to become Licensed Practical Nurses in less time, offering a quicker pathway to patient care roles.

Specializing in growing fields is also easier with online options. For example, accelerated msn psychiatric np programs can help you qualify as a nurse practitioner specializing in mental health through intensive, streamlined curriculums.

If you are more interested in the administrative side of healthcare, a bachelors in healthcare administration can open doors to leadership positions in hospitals, clinics, and beyond—all while studying online at your own pace.

Best Scientists Citing Val Gebski

Trending Scientists

Recently Published Articles